Wells Fargo lowered the firm’s price target on Bristol Myers (BMY) to $53 from $62 and keeps an Equal Weight rating on the shares. The firm says the long-term growth profile remains an issue for Bristol Myers, as growth portfolio is slowing down and legacy decline is accelerating. Recent trial setbacks emphasize the need for more external pipeline, Wells adds.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- Bristol-Myers Squibb: Hold Rating Amidst Strong Q1 Performance and Long-Term Growth Challenges
- Bristol Myers Squibb Q1 2025 Financial Results Overview
- Bristol-Myers Squibb’s Earnings Call: Strong Growth Amid Challenges
- Unusually active option classes on open April 24th
- Morning Movers: Mobileye jumps following first quarter earnings